Best Peptides for Fat Loss
GLP-1 agonists like semaglutide and tirzepatide dominate the conversation around peptides and fat loss — and with good reason, given their clinical trial results. But they are not the only peptides used in fat loss and metabolic health contexts. A separate category of growth hormone–related peptides has attracted significant interest in functional medicine and body composition circles, with a very different mechanism, a different evidence base, and a different patient profile.
This guide maps all of them — honestly. That means presenting what the clinical evidence actually shows for each category, not what the marketing says. Some have strong data. Some have promising but limited data. And one has clinical trial data that flatly didn't support its primary claim. Knowing the difference is the whole point.
Key Takeaways
- GLP-1 receptor agonists (semaglutide, tirzepatide) have the strongest evidence for total body fat reduction — backed by large RCTs and FDA approval.
- Tesamorelin has the strongest evidence among growth hormone–related peptides specifically for visceral fat reduction — about 15–20% VAT reduction over 26 weeks in clinical trials.
- CJC-1295 and Ipamorelin elevate growth hormone and IGF-1, which are mechanistically linked to fat metabolism — but direct human RCT evidence for meaningful fat loss is limited.
- AOD-9604 failed its primary endpoint in a 24-week Phase II obesity trial. Its evidence base is the weakest of the commonly promoted fat loss peptides.
- No non-GLP-1 peptide approaches the scale of fat loss seen with semaglutide or tirzepatide in clinical trials.
- Growth hormone secretagogues may be most valuable as adjuncts to GLP-1 therapy — supporting lean mass preservation while GLP-1 drives overall weight loss.
How to Read This Guide
Each peptide below is assessed on two dimensions: evidence level (how strong the human clinical data is) and regulatory status (whether a prescription is needed and what the FDA says). These are displayed as colour-coded badges throughout.
Category 1: GLP-1 Receptor Agonists
The most evidence-backed peptides for fat loss are not the ones most commonly discussed in fitness and biohacking communities — they are the GLP-1 receptor agonists that have transformed obesity pharmacology. Any honest guide to fat loss peptides must start here, because nothing else comes close in terms of clinical evidence.
Semaglutide (Ozempic / Wegovy)
Mechanism
GLP-1 receptor agonist. Reduces appetite via hypothalamic pathways, slows gastric emptying, stimulates glucose-dependent insulin secretion. Acts on GLP-1 receptors in the gut, pancreas, and brain simultaneously.
Fat Loss Evidence
In the STEP-1 trial (n=1,961 adults with obesity without diabetes), semaglutide 2.4mg produced a mean total body weight reduction of 14.9% at 68 weeks — the majority of which was fat mass. Real-world studies consistently show 14–17% weight reduction at 12 months with good adherence.[1]
Tirzepatide (Mounjaro / Zepbound)
Mechanism
Dual GLP-1 and GIP receptor agonist. GIP receptor activation in adipose tissue appears to enhance fat mobilisation synergistically with GLP-1's appetite effects, which is the primary mechanistic explanation for its superior fat loss outcomes compared to semaglutide alone.
Fat Loss Evidence
SURMOUNT-1 showed up to 22.5% total body weight reduction at 72 weeks, with approximately 75% of weight lost coming from fat mass. The SURMOUNT-5 head-to-head trial confirmed tirzepatide's superiority over semaglutide — producing 20.2% vs 13.7% weight loss respectively over 72 weeks.[2]
Category 2: Growth Hormone–Related Peptides
A separate cluster of peptides targets fat loss through the growth hormone axis rather than appetite suppression. These work by stimulating the pituitary to release more of its own growth hormone, which in turn activates lipolysis (fat breakdown) and promotes favourable body composition. They produce a fundamentally different type of effect from GLP-1s — more targeted visceral fat reduction and lean mass support rather than broad total weight loss.
Tesamorelin (Egrifta)
Mechanism
Synthetic analogue of growth hormone–releasing hormone (GHRH). Binds to GHRH receptors in the pituitary, stimulating the release of endogenous growth hormone in a pulsatile, physiologically appropriate pattern. Elevated GH activates hormone-sensitive lipase and enhances fatty acid oxidation, with a clinically observed selectivity for visceral adipose tissue (VAT) — the deep abdominal fat surrounding organs — rather than subcutaneous fat.
Fat Loss Evidence
Tesamorelin is the best-studied non-GLP-1 peptide for fat reduction. In the pivotal NEJM trial (n=412 HIV patients with abdominal lipodystrophy), daily tesamorelin for 26 weeks produced a 15.2% reduction in visceral adipose tissue compared to a 5.0% increase in the placebo group — a highly significant difference. Two Phase III trials showed VAT reductions of 11.7–19.6% over 26 weeks. Crucially, subcutaneous fat was largely preserved, and skeletal muscle area and density both improved significantly in treatment responders.[3]
Honest Limitations
Almost all robust evidence comes from HIV-associated lipodystrophy populations — a specific condition involving antiretroviral drug–induced fat redistribution. Data in the general non-HIV population with visceral obesity is much more limited. Tesamorelin is FDA-approved only for HIV lipodystrophy. Off-label use for general visceral fat reduction is practised but based on extrapolation, not direct trial evidence. It also carries a clinically noted risk of mild glucose elevation, particularly relevant for patients with pre-diabetes.[4]
CJC-1295 + Ipamorelin
Mechanism
CJC-1295 is a GHRH analogue that produces sustained growth hormone release. Ipamorelin is a ghrelin receptor agonist (growth hormone secretagogue) that stimulates a separate pituitary GH pulse. Used together, they produce synergistic and prolonged GH elevation through two independent pathways — which is why they are typically combined rather than used alone. Elevated GH drives IGF-1 production, which promotes lipolysis, protein synthesis, and favourable body composition changes.
Fat Loss Evidence
The evidence for direct fat loss is extrapolated rather than directly demonstrated. A randomised trial showed CJC-1295 produced 2–10 fold increases in GH and 1.5–3 fold increases in IGF-1 sustained over 6–9 days — confirming the mechanism is active. Because elevated GH is well established to promote lipolysis in other clinical contexts, the biological rationale is sound. However, no large randomised controlled trial has measured fat mass changes directly as a primary endpoint for this combination in otherwise healthy adults with obesity.[5]
Honest Limitations
The fat loss claims for CJC-1295/Ipamorelin rest primarily on the well-established physiology of growth hormone and extrapolation from that biology — not on fat mass RCT outcomes in the target population. This is a meaningful distinction. GH secretagogues may be most valuable for their lean mass preservation effects during caloric restriction (including GLP-1 therapy) rather than as standalone fat loss agents.
Sermorelin
Mechanism
A synthetic fragment of GHRH (amino acids 1–29) that stimulates the pituitary to release endogenous growth hormone. Sermorelin has a shorter half-life than CJC-1295 — typically administered daily at night to coincide with the body's natural nocturnal GH pulse. It is often described as a gentler, more physiological GH stimulus than CJC-1295.
Fat Loss Evidence
Sermorelin's FDA-approved indication (now withdrawn from the market) was for growth hormone deficiency in children. Evidence for fat loss in adults with obesity is limited to smaller studies and observational data. Some clinical data shows improvements in body composition, sleep quality, and energy in adults with low-normal GH levels — but large fat loss RCTs do not exist for sermorelin in general obesity populations.
Where It Fits
Sermorelin is primarily used in anti-aging and wellness medicine for adults with age-related growth hormone decline. Its role in fat loss is best understood as part of a broader body composition improvement rather than a targeted fat loss intervention. It is typically a more accessible and lower-risk GH secretagogue option than tesamorelin for non-HIV patients.
Category 3: AOD-9604 — A Cautionary Case Study
AOD-9604
Mechanism
AOD-9604 is a synthetic fragment of human growth hormone — specifically the C-terminal region (amino acids 176–191) — that was designed to replicate the fat-metabolising properties of growth hormone without its effects on blood sugar or IGF-1. The theory was that this fragment could stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without the side effects associated with full growth hormone administration.
What the Evidence Actually Shows
AOD-9604 is the most widely marketed "fat-burning peptide" in wellness circles — and also the one with the weakest clinical evidence base. Development of AOD-9604 as a pharmaceutical drug was discontinued in 2007 when Phase II clinical trials in 536 adults with obesity over 24 weeks failed to demonstrate significant weight loss compared to placebo at the primary endpoint.[6]
A smaller earlier trial showed modest separation from placebo (approximately 2.6kg vs 0.8kg at 12 weeks, oral formulation), and animal studies do show lipolytic activity — which is likely why interest has persisted. But no Phase III trial was ever conducted, and the compound failed to advance to drug approval precisely because its clinical performance did not match its theoretical promise.
Honest Assessment
AOD-9604 is frequently marketed with claims that significantly outpace its evidence. The gap between what rodent studies suggest and what human trials demonstrated is wide and clinically important. That does not mean it has no biological activity — it means its human clinical performance has not been validated to the standard required for medical use. Patients considering it should weigh this context carefully.
Head-to-Head: Evidence and Access Summary
| Peptide | Primary Fat Loss Mechanism | Human Evidence for Fat Loss | FDA Status |
|---|---|---|---|
| Tirzepatide | GLP-1 + GIP appetite suppression; fat mobilisation | Strong — large RCTs; 18–22% weight loss | FDA-approved (Zepbound) |
| Semaglutide | GLP-1 appetite suppression; gastric slowing | Strong — large RCTs; 14–15% weight loss | FDA-approved (Wegovy) |
| Tesamorelin | GH stimulation → visceral fat lipolysis | Moderate — Phase III RCTs in HIV; 15–20% VAT reduction | FDA-approved for HIV lipodystrophy; off-label for others |
| CJC-1295 + Ipamorelin | GH/IGF-1 elevation → lipolysis; lean mass support | Limited — GH elevation confirmed; fat loss extrapolated | Compoundable (Category 1, Feb 2026); Rx required |
| Sermorelin | GH stimulation → body composition improvement | Limited — observational and small studies only | Compoundable (Category 1); Rx required |
| AOD-9604 | GH fragment → lipolysis (theoretical) | Weak — failed Phase II obesity RCT in 536 subjects | Not approved; research grade only |
The Case for Combining GLP-1s with GH Secretagogues
One emerging approach in clinical practice is combining GLP-1 medications with GH secretagogues — the logic being that GLP-1s drive the caloric deficit and overall fat loss while GH peptides help preserve or increase lean mass during that deficit. This combination is not yet evaluated in published RCTs, but the mechanistic rationale is well grounded.
As we discussed in the article on muscle loss, approximately 25–45% of weight lost on GLP-1 therapy comes from lean mass rather than fat. GH secretagogues directly counter this by stimulating muscle protein synthesis and supporting lean tissue — which is precisely where their evidence base is strongest. Combining the two addresses the most clinically relevant limitation of GLP-1 monotherapy.
Which Peptide Fits Which Goal?
Goal-Based Guidance
The Bottom Line on Fat Loss Peptides
The honest hierarchy is straightforward: GLP-1 agonists produce the most clinically meaningful and evidence-backed fat loss of any peptide category — by a significant margin. If total weight and fat reduction is the goal, semaglutide and tirzepatide are the options with the most compelling case.
Tesamorelin sits in a legitimate second tier — with real Phase III trial evidence for visceral fat reduction, FDA approval for a specific indication, and a meaningful lean mass preservation advantage. Its limitation is the evidence base being HIV-specific, and the off-label evidence gap for general populations.
CJC-1295, Ipamorelin, and Sermorelin have a sound mechanistic rationale and some human evidence for GH elevation, but direct RCT evidence for meaningful fat loss in otherwise healthy adults is currently insufficient to make strong claims. Their strongest clinical role may be as adjuncts to GLP-1 therapy rather than standalone fat loss agents.
AOD-9604 failed its primary clinical endpoint. That is a meaningful data point that should inform how much confidence anyone places in the claims made about it.
Want to understand which peptide approach fits your goals?
Our free quiz helps you think through your situation before speaking to a clinician.
Take Our Peptide Plan Quiz →References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384:989–1002. Available from: https://pubmed.ncbi.nlm.nih.gov/33567185/
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36. Available from: https://pubmed.ncbi.nlm.nih.gov/40353578/
- Falutz J, et al. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. N Engl J Med. 2007;357:2359–2370. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa072375
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380–389. Available from: https://pubmed.ncbi.nlm.nih.gov/25038357/
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. Available from: https://pubmed.ncbi.nlm.nih.gov/16980942/
- Lanosterol RJ, et al. AOD-9604 Phase II clinical trial results. As cited in: FormBlends Medical Team. The Fat Loss Trifecta: Peptide Stacks for Body Recomposition. 2026. Available from: https://www.formblends.com
- NCBI Bookshelf. Clinical Review Report: Tesamorelin (Egrifta). Canadian Agency for Drugs and Technologies in Health. 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539127/